BioCentury
ARTICLE | Company News

Acetylon, Celgene deal

December 9, 2016 10:05 PM UTC

Acetylon said Celgene will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston, Mass.). Celgene will gain rights to Acetylon's lead candidates, oral HDAC6 inhibitors ricolinostat (ACY-1215) and citarinostat (ACY-241), in cancer, neurodegeneration and autoimmune indications. Both are in development for multiple myeloma (MM); ricolinostat is in Phase I testing and citarinostat is in Phase II testing...